Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

david5772 Feb. 27 at 12:21 PM

$CRVO management of a company this size doesn’t think strategically about dilution. They’re about survival, not making 10 dollars instead of 6.

1 · Reply

Doki0926 Feb. 26 at 10:43 PM

$CRVO when will this return to 10❓❓❓❓‼️‼️‼️‼️‼️

0 · Reply

Messerschmittbf109 Feb. 26 at 4:39 PM

$CRVO embarrassing ..a normal b@ard would have gotten out of the way …

0 · Reply

BPler Feb. 26 at 4:07 PM

$CRVO I shared in the past that I also add. If so many of you are so bearish why not shorting it and show some proof to see later how it turned out?

1 · Reply

Scorpole Feb. 26 at 3:22 PM

$CRVO If we are close to the bottom, the volume will dry up. But the volume has increased, which for me indicates it is going to be very ugly. An offering between $1-2 imo.

1 · Reply

CWL123 Feb. 26 at 2:46 PM

$CRVO no end in sight after the bell friday dilution is what i am thinking

0 · Reply

BPler Feb. 26 at 9:10 AM

$CRVO ist auch seit kurzem auf Trade Republic für alle deutschen Trader 🙂 https://m.aktiencheck.de/analysen/Artikel-Diffusion_Pharmaceuticals_Aktie_Erfolgsspur_gefestigt-19506839

0 · Reply

SteveO_TX_to_FL Feb. 25 at 11:12 PM

$CRVO huge volume (relative to 10 day MA), with a big drop. Maybe dilution financing has been leaked. Maybe it’s just random. I’ve seen all the preclinical and clinical data and I believe the company is taking the necessary steps toward a blockbuster. You didn’t like when I said it before, but I believe by June 2027 (or earlier) is when the value will absolutely pop. If dilution is in the works, my share count will multiply greatly after the drop. We’ll see!

2 · Reply

Pharoh42 Feb. 25 at 10:26 PM

$CRVO Down 52% in 3 months I have no idea why these people still getting paid ?!!

0 · Reply

Pharoh42 Feb. 25 at 10:24 PM

$CRVO This is turning into a clown show

0 · Reply

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

SCYX

Dec 4, 2025, 5:00 PM EST - 3 months ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 2, 2025, 7:00 AM EST - 3 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Nov 24, 2025, 7:00 AM EST - 3 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 20, 2025, 8:00 AM EDT - 4 months ago

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 11:54 AM EDT - 5 months ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 5 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 5 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 5 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 6 months ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 7 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 7 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 8 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 10 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 11 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 1 year ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 1 year ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 1 year ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 1 year ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 2 years ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 2 years ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 2 years ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

david5772 Feb. 27 at 12:21 PM

$CRVO management of a company this size doesn’t think strategically about dilution. They’re about survival, not making 10 dollars instead of 6.

1 · Reply

Doki0926 Feb. 26 at 10:43 PM

$CRVO when will this return to 10❓❓❓❓‼️‼️‼️‼️‼️

0 · Reply

Messerschmittbf109 Feb. 26 at 4:39 PM

$CRVO embarrassing ..a normal b@ard would have gotten out of the way …

0 · Reply

BPler Feb. 26 at 4:07 PM

$CRVO I shared in the past that I also add. If so many of you are so bearish why not shorting it and show some proof to see later how it turned out?

1 · Reply

Scorpole Feb. 26 at 3:22 PM

$CRVO If we are close to the bottom, the volume will dry up. But the volume has increased, which for me indicates it is going to be very ugly. An offering between $1-2 imo.

1 · Reply

CWL123 Feb. 26 at 2:46 PM

$CRVO no end in sight after the bell friday dilution is what i am thinking

0 · Reply

BPler Feb. 26 at 9:10 AM

$CRVO ist auch seit kurzem auf Trade Republic für alle deutschen Trader 🙂 https://m.aktiencheck.de/analysen/Artikel-Diffusion_Pharmaceuticals_Aktie_Erfolgsspur_gefestigt-19506839

0 · Reply

SteveO_TX_to_FL Feb. 25 at 11:12 PM

2 · Reply

Pharoh42 Feb. 25 at 10:26 PM

$CRVO Down 52% in 3 months I have no idea why these people still getting paid ?!!

0 · Reply

Pharoh42 Feb. 25 at 10:24 PM

$CRVO This is turning into a clown show

0 · Reply

Ghostofgreg1 Feb. 25 at 10:04 PM

$CRVO A year and a half ago I wonder if he was in on this running scam all along Thats what this is One long running scam

1 · Reply

Messerschmittbf109 Feb. 25 at 9:02 PM

$CRVO board and analysts are so funny A joke stock

0 · Reply

Messerschmittbf109 Feb. 25 at 8:44 PM

$CRVO pieces of sh i tz…. Vacuum

1 · Reply

Messerschmittbf109 Feb. 25 at 7:29 PM

$BBNX $CRDF $CRVO $MANKIND.NSE it is for mankind

1 · Reply

Messerschmittbf109 Feb. 25 at 7:28 PM

$BBNX $CRDF $CRVO $MANKIND.NSE Another stock with a monstrous TP nice work Wain wright HC Wainwright reiterated a "buy" rating and set a $11 price target, implying roughly a 199.65% upside from the prior close.

0 · Reply

BPler Feb. 25 at 3:58 PM

$CRVO ER call will bring more light into the fiancing part, even for a buyout the premium would be multiple x: Seeing instutional buying being still strong with big names gives me enough confidence.

1 · Reply

Messerschmittbf109 Feb. 25 at 3:55 PM

$CRVO CervoMed Inc. (NASDAQ:CRVO) Receives $22.17 Average PT from Brokerages Posted by ABMN Staff on Feb 25th, 2026 CervoMed logoShares of CervoMed Inc. (NASDAQ:CRVO – Get Free Report) have earned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, http://MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company

0 · Reply

Disinformation_Consumer Feb. 25 at 3:45 PM

$CRVO Short interest is spiking and the share price is down 6%. The offering is about to happen.

1 · Reply

BPler Feb. 24 at 1:55 PM

Seeing lately many biotechs run like $VIR (Phase 1) buidling billons in valuation while $CRVO is still at 42 Mio. despite all the positive news with data, alignment with FDA for Phase 3 awards, grants, insider buying and more potential new drug application fields adding. Investing in biotech takes more patients than in other fields, so congrats to $VIR and let's see how it goes from here!

1 · Reply

LowCountryHooker Feb. 24 at 1:27 PM

$CRVO We’re thrilled that neflamapimod has been selected by the UK’s EXPERTS-ALS platform to assess its potential as an ALS treatment. Funded by the UK government and leading motor neuron disease charities, EXPERTS-ALS conducts an ongoing clinical trial at sites throughout the UK to rapidly identify promising drug candidates and expedite their development. Neflamapimod was selected based on its mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in relevant neurotoxicity models. This will be the first clinical study to evaluate neflamapimod in ALS. ALS is a devastating disease for people with the condition and their families, and we’re proud to partner with EXPERTS-ALS. You can read more here: https://lnkd.in/e455yvzN #ALS #neflamapimod

0 · Reply

BPler Feb. 24 at 1:17 PM

$CRVO https://www.ad-hoc-news.de/boerse/news/ueberblick/cervomed-s-pivotal-year-clinical-and-financial-milestones-on-the-horizon/68605676

0 · Reply

Messerschmittbf109 Feb. 23 at 5:17 PM

$CRDF $GOSS wen wainwright watch… it is the time to cut the loss $BBNX $CRVO

0 · Reply

Market Cap	40.62M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	117,400
Avg Vol	75,158
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	30%
Beta	-0.82
Analysts	Strong Sell
Price Target	$22.43